| From Responsible Research and Innovation to responsibility by design BC Stahl, S Akintoye, L Bitsch, B Bringedal, D Eke, M Farisco, ... Journal of Responsible Innovation 8 (2), 175-198, 2021 | 58 | 2021 |
| New regulation for clinical stem cell research in China: expected impact and challenges for implementation A Rosemann, M Sleeboom-Faulkner Regenerative medicine 11 (1), 5-9, 2016 | 46 | 2016 |
| Comparing national home-keeping and the regulation of translational stem cell applications: an international perspective M Sleeboom-Faulkner, CK Chekar, A Faulkner, C Heitmeyer, M Marouda, ... Social Science & Medicine 153, 240-249, 2016 | 42 | 2016 |
| Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations A Rosemann, G Bortz, F Vasen, M Sleeboom-Faulkner Regenerative medicine 11 (7), 647-657, 2016 | 39 | 2016 |
| The pluralization of the international: resistance and alter-standardization in regenerative stem cell medicine A Rosemann, N Chaisinthop Social Studies of Science 46 (1), 112-139, 2016 | 33 | 2016 |
| Why regenerative stem cell medicine progresses slower than expected A Rosemann Journal of Cellular Biochemistry 115 (12), 2073-2076, 2014 | 32 | 2014 |
| Heritable Genome Editing in a Global Context: National and International Policy Challenges A Rosemann, A Balen, B Nerlich, C Hauskeller, M Sleeboom‐Faulkner, ... Hastings Center Report 49 (3), 30-42, 2019 | 29 | 2019 |
| Standardization as situation-specific achievement: Regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine A Rosemann Social Science & Medicine 122, 72-80, 2014 | 28 | 2014 |
| Industrial biotechnology: to what extent is responsible innovation on the agenda? A Rosemann, S Molyneux-Hodgson Trends in biotechnology 38 (1), 5-7, 2020 | 25 | 2020 |
| Medical innovation and national experimental pluralism: insights from clinical stem cell research and applications in China A Rosemann BioSocieties 8, 58-74, 2013 | 20 | 2013 |
| Alter-standardizing clinical trials: the gold standard in the crossfire A Rosemann Science as Culture 28 (2), 125-148, 2019 | 17 | 2019 |
| Exploring the social, ethical, legal, and responsibility dimensions of artificial intelligence for health-a new column in Intelligent Medicine A Rosemann, X Zhang Intelligent Medicine 2 (02), 103-109, 2022 | 16 | 2022 |
| Modalities of value, exchange, solidarity: the social life of stem cells in China A Rosemann New Genetics and Society 30 (2), 181-192, 2011 | 16 | 2011 |
| Global diversification in medicine regulation: insights from regenerative stem cell medicine A Rosemann, F Vasen, G Bortz Science as Culture 28 (2), 223-249, 2019 | 15 | 2019 |
| The regulatory and legal situation of human embryo, gamete and germ line gene editing research and clinical applications in the People’s Republic of China A Rosemann, L Jiang, X Zhang University of Sussex, 2017 | 14 | 2017 |
| Attitudes towards the donation of human embryos for stem cell research among Chinese IVF patients and students A Rosemann, H Luo Journal of Bioethical Inquiry 15 (3), 441-457, 2018 | 13 | 2018 |
| Human embryo gene editing in China: The uncertain legal status of the embryo L Jiang, A Rosemann Biosocieties 14 (1), 46-66, 2019 | 12 | 2019 |
| Regulatory developments for nonhematopoietic stem cell therapeutics: perspectives from the EU, the USA, Japan, China, India, Argentina, and Brazil A Rosemann, G Bortz, F Vasen A Roadmap to Non-Hematopoietic Stem Cell-Based Therapeutics, 463-492, 2019 | 11 | 2019 |
| Regulatory capacity building and the governance of clinical stem cell research in China M Sleeboom-Faulkner, H Chen, A Rosemann Science and Public Policy 45 (3), 416-427, 2018 | 10 | 2018 |
| Stem cell treatments for neurodegenerative diseases: challenges from a science, business and healthcare perspective A Rosemann Neurodegenerative Disease Management 5 (2), 85-87, 2015 | 9 | 2015 |
